TWILIGHT: Ticagrelor Alone Reduces Bleeding, Does Not Increase Ischemic Events, Compared to Ticagrelor Plus Aspirin in High-Risk Patients After PCI
SAN FRANCISCO – Ticagrelor alone was superior to ticagrelor plus aspirin in preventing clinically relevant bleeding events, and showed no difference in ischemic events, in patients at high risk for experiencing bleeding or ischemic events after undergoing percutaneous coronary intervention (PCI), according to late-breaking trial results presented Thursday at Transcatheter Cardiovascular Therapeutics (TCT) 2019.